EAU 2022 | Salvage treatment options for PSMA-avid lesions
Tobias Maurer, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, comments on modern diagnostic and therapeutic approaches in the treatment of prostate cancer. Dr Maurer discusses how salvage surgery after biochemical recurrence following radical prostatectomy is not the current standard approach for the treatment of prostate cancer. However, with the advancement of imaging, such as PSMA-PET, local salvage treatments in which metastases are directly targeted are being brought into focus. Dr Maurer also talks on recent work which show that salvage surgery, following biochemical recurrence after radical prostatectomy, results in a significant decrease in prostate-specific antigen (PSA) and prolonged PSA-free periods in patients with PSMA-avid lesions and discusses the factors which influence the selection of patients for treatment with salvage therapies. This interview took place at the European Association of Urology (EAU) Meeting 2022.
Disclosures
Dr Maurer reports the following conflicts of interest:
Advisory roles: Advanced Accelerator Applications International S.A., Novartis, Telix, ROTOP Pharma, GEMoAb, Astellas, Blue Earth Diagnostics, ABX
Speaker roles for Bayer, Sanofi-Aventis, Astellas, Phillips
